| 产品描述: | 4E2RCat是eIF4E-eIF4G相互作用的抑制剂,IC50值为13.5 μM。 |
| 靶点: |
IC50: 13.5 μM (eIF4E-eIF4G) |
| 体外研究: |
4E2RCat prevents the interaction between eIF4E (the cap-binding protein) and eIF4G (a large scaffolding protein), inhibiting cap-dependent translation. It significantly decreases human coronavirus 229E (HCoV-229E) replication, reducing the percentage of infected cells and intra- and extracellular infectious virus titers. 4E2RCat inhibits cap-dependent translation in a dose-dependent manner. 4E2RCat inhibits cap-dependent FF translation but not EMCV IRES-driven Ren translation. 4E2RCat inhibits coronavirus replication in a dose- and time-dependent manner. |
| 体内研究: |
4E2RCat inhibits protein synthesis in vivo and it is not a consequence of increased cell death. |
| 参考文献: |
1. Cencic R, et al. Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication. J Virol. 2011 Jul;85(13):6381-9. |
| 溶解性: |
soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.193 ml |
10.967 ml |
21.933 ml |
| 5 mM |
0.439 ml |
2.193 ml |
4.387 ml |
| 10 mM |
0.219 ml |
1.097 ml |
2.193 ml |
| 50 mM |
0.044 ml |
0.219 ml |
0.439 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |